RightFit
RecruitingPhase not listed

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years to 90 Years
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study is developing a home blood test that measures p-tau217, a protein linked to Alzheimer's disease. It compares blood collected with the Tasso device to blood drawn from a vein in people with and without Alzheimer's disease.

This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You are 40 to 90 years old.
  • You have Alzheimer's disease confirmed by a brain scan or spinal fluid test for amyloid, a protein that builds up in the brain; are a healthy volunteer; or have memory or thinking problems not caused by Alzheimer's and test negative for amyloid.
  • You can give blood using both the Tasso device and a needle in a vein.
  • A caregiver can give consent or help if needed.

Who can't join

  • You have health conditions affecting your body that are not under control.
  • You had surgery or stayed in a hospital in the past 3 months.
  • You took part in another dementia drug trial in the past 2 months.
  • You are pregnant.
  • You have ever used donanemab or lecanemab, medicines for Alzheimer's disease.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed Exclusion Criteria: * Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use

Study sites (5)

IL

MI

NC